Post the big ticket acquisition of Arysta lifesciences last year, UPL has reported a subdued set of Q4 results. While the operating performance (excluding Arysta remained healthy), the combined numbers remained impacted. Sakshi Batra does a 3 point analysis of the earnings fine print and the outlook on the company.